Lipid-lowering agents (PCSK9 inhibitors)
- Very potent LDL-lowering therapies
- Alirocumab/evolocumab are injectable mAbs
- Major role in ASCVD + familial hypercholesterolemia
- LDL often falls ~50–60%
- Reduce CV events when added to statins
- Injection reactions; otherwise well tolerated
- Cost/access often determines use
Class at a glance
- Very potent LDL-lowering therapies
Members / distinctions
- Alirocumab/evolocumab are injectable mAbs
- Major role in ASCVD + familial hypercholesterolemia
Clinical role
- Reduce CV events when added to statins
- Injection reactions; otherwise well tolerated
- Cost/access often determines use
Practical pearls
Self-check
- What do Lipid-lowering agents (PCSK9 inhibitors) primarily reduce?
CV events when added to statins.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
